Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Clinical Pathways GPS

How Clinical Pathways Can Support Bundled Payment Models

09/13/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

As the Blue Ribbon report of the Cancer Moonshot1 called for in 2016, we need to build the national cancer data ecosystem that is equal in dimension to the disease burden cancer imposes on society and the resources...

As the...

09/13/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Communicating More Through Clinical Pathways to Advance Value-Based Health Care

08/22/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The Food and Drug Administration (FDA) recently published guidance that clarifies how pharmaceutical manufacturers can share product information with payers while remaining compliant with FDA rules on...

The...

08/22/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Understanding the "American Patients First‚" Blueprint: Implications for Clinical Pathways

06/14/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

With the release of President Trump’s “American Patients First” strategy blueprint to tackle US drug pricing and health care costs, clinical pathway developers and professionals will need to take this proposed plan...

With...

06/14/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Emerging Care Delivery Models Where Payers and Providers Become One

05/15/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The trend of reducing health care costs through global capitation and aggressive contracting from payer/provider integration has and will continue to expand in the health care market. This combination will provide a...

The...

05/15/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Dealing With New Formulary Types: Health System Outpatient Formularies

04/17/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Developers and utilizers of clinical pathways need to understand that formulary systems encompass more than merely a list of medications approved by a managed care organization. These stakeholders should also factor...

...

04/17/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Targeting the Quadruple Aim Through Clinical Pathways

03/15/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

All health care professionals recognize the Triple Aim, which is focused on outcomes, costs, and patient experiences. However, a fourth aim was added, which focuses on an essential, yet often forgotten, contribution...

All...

03/15/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Who Really Controls Treatment Selection? It`s Not Always Who You Think

02/15/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

New policies and legislation related to health care reform mean that control over treatment selections may also shift within different markets. For professionals creating a clinical pathway for a disease state, it is...

New...

02/15/2018

Journal of Clinical Pathways

Clinical Pathways GPS

How New Rules for 2018 Will Impact Clinical Pathways

12/13/2017

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

12/13/2017

Journal of Clinical Pathways

Clinical Pathways GPS

Atypical Players in the Treatment Landscape

11/27/2017

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

CVS pharmacy recently made an offer to acquire Aetna Health Plan for $66 billion.1 This is a true game changer for two reasons: first, it represents the most significant national integration of service provider and...

CVS...

11/27/2017

Journal of Clinical Pathways

Clinical Pathways GPS

Looking for Leadership in Developing Pathways

10/16/2017

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Scott Guerin , PhD;

A clinical pathway can be defined as an “optimal sequencing and timing of interventions by physicians, nurses, and other staff for a particular diagnosis or procedure.” As organizations new to pathways look to...

A...

10/16/2017

Journal of Clinical Pathways